PBMWW
Psyence Biomedical Ltd. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
1.65
52W High
$0.06
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Psyence Biomedical Ltd. Warrant
Psyence Biomedical Ltd. is a frontrunner in the emerging psychedelic sector, dedicated to the research, development, and commercialization of psilocybin-based therapies targeting critical mental health issues such as anxiety and depression. With a robust commitment to scientific integrity and regulatory compliance, the company is well-equipped to capitalize on its extensive intellectual property portfolio as public perceptions of psychedelics shift. Psyence aims to forge a pathway in the expanding mental health treatment market, seizing opportunities presented by the growing acknowledgment of psychedelics' therapeutic potential in clinical settings.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.15M |
| Operating Margin | 0.00% |
| Return on Equity | -74.30% |
| Return on Assets | -34.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $39.62 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 142,970 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
36.81%
HV 20-Day
107.64%
HV 30-Day
97.76%
HV 60-Day
185.08%
HV Rank
—
Volatility is currently contracting
Data last updated: 6/13/2026